Omeros (OMER) Stock Forecast: StockMap's 2-Week Call
OMER stock forecast: StockMap's model leans Underperform on Omeros for the two weeks after the Nov 13 close, toward OMER trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 3 two-week windows on OMER since Sep 24; by chance, a call on the same dates was right 51% of the time.
Omeros last closed at $17.49, -2.78% on the session.
Against the IVW growth benchmark the position is -1.87% over the forecast window.
Omeros' market cap is $1.27B as of November 13, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -39 (too close to call).
Where OMER sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
24 daily calls for OMER so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Omeros in the 63rd percentile on valuation and the 10th percentile on return on equity, where 100 is best.
Omeros is classified under Health Care / Pharmaceuticals.
StockMap tracks Omeros as the 60th largest of the 152 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 73 Moderate Underperform, 49 Neutral and 30 Strong Underperform.
On that composite Omeros ranks 97th of 152 in the group, against a group median of -0.33.